Portal de Periódicos da CAPES

Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine

2021; Elsevier BV; Volume: 30; Issue: 8 Linguagem: Inglês

10.1016/j.jstrokecerebrovasdis.2021.105906

1532-8511

Leonor Dias, Ricardo Soares-dos-Reis, João Meira Gonçalves, Diana Ferrão, Pedro Ribeirinho-Soares, Ana Pastor, Guilherme Gama, Luísa Fonseca, Vítor Fagundes, Marta Carvalho,

Venous Thromboembolism Diagnosis and Management

The development of SARS-CoV-2 vaccines has raised several concerns regarding venous thromboembolism, namely cerebral venous thrombosis. Although cerebral venous thrombosis has been reported after administration of a viral vector vaccine, due to a possible auto-immune mechanism inducing thrombocytopenia, the same has not happened in mRNA vaccines. We report two cases of cerebral venous thrombosis, shortly after administration of mRNA vaccine. In both patients, there was no evidence of thrombocytopenia or antiplatelet antibodies, and alternative causes for cerebral venous thrombosis were found. As such, despite the temporal relation of both cases to vaccine administration, these types of cerebral venous thrombosis do not seem to be pathophysiological different from cerebral venous thrombosis not associated to SARS-CoV-2 vaccination. Continuous pharmacovigilance is necessary to monitor possible new events and clarify this association.